1. Home
  2. RGNX vs SIBN Comparison

RGNX vs SIBN Comparison

Compare RGNX & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • SIBN
  • Stock Information
  • Founded
  • RGNX 2008
  • SIBN 2008
  • Country
  • RGNX United States
  • SIBN United States
  • Employees
  • RGNX N/A
  • SIBN N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • SIBN Medical/Dental Instruments
  • Sector
  • RGNX Health Care
  • SIBN Health Care
  • Exchange
  • RGNX Nasdaq
  • SIBN Nasdaq
  • Market Cap
  • RGNX 459.1M
  • SIBN 547.3M
  • IPO Year
  • RGNX 2015
  • SIBN 2018
  • Fundamental
  • Price
  • RGNX $7.62
  • SIBN $13.25
  • Analyst Decision
  • RGNX Strong Buy
  • SIBN Strong Buy
  • Analyst Count
  • RGNX 12
  • SIBN 7
  • Target Price
  • RGNX $36.00
  • SIBN $23.43
  • AVG Volume (30 Days)
  • RGNX 1.7M
  • SIBN 291.5K
  • Earning Date
  • RGNX 11-06-2024
  • SIBN 11-12-2024
  • Dividend Yield
  • RGNX N/A
  • SIBN N/A
  • EPS Growth
  • RGNX N/A
  • SIBN N/A
  • EPS
  • RGNX N/A
  • SIBN N/A
  • Revenue
  • RGNX $84,327,000.00
  • SIBN $157,035,000.00
  • Revenue This Year
  • RGNX $2.34
  • SIBN $21.24
  • Revenue Next Year
  • RGNX $243.67
  • SIBN $15.59
  • P/E Ratio
  • RGNX N/A
  • SIBN N/A
  • Revenue Growth
  • RGNX N/A
  • SIBN 18.98
  • 52 Week Low
  • RGNX $7.21
  • SIBN $11.70
  • 52 Week High
  • RGNX $28.80
  • SIBN $21.70
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 36.08
  • SIBN 47.44
  • Support Level
  • RGNX $8.06
  • SIBN $13.10
  • Resistance Level
  • RGNX $10.52
  • SIBN $14.02
  • Average True Range (ATR)
  • RGNX 0.76
  • SIBN 0.67
  • MACD
  • RGNX -0.19
  • SIBN -0.02
  • Stochastic Oscillator
  • RGNX 12.39
  • SIBN 25.00

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Share on Social Networks: